Skip to main content

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

CBE ID
0108
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Spring 2026
1.6 Measure Description

Percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which is within 30 days of when the first ADHD medication was dispensed.
An Initiation Phase Rate and Continuation and Maintenance Phase Rate are reported.

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.8 Level of Analysis
      1.20 Types of Data Sources
      1.14 Numerator

      Among children newly prescribed ADHD medication, those who had timely and continuous follow-up visits.

      1.15 Denominator

      Children 6-12 years of age newly prescribed ADHD medication.

      Exclusions

      Children who had an acute inpatient encounter for mental health or chemical dependency following the Index Prescription Start Date

      Children with a diagnosis of narcolepsy: Many of the medications used to identify patients for the denominator of this measure are also used to treat narcolepsy. Children with narcolepsy who are pulled into the denominator are then removed by the narcolepsy exclusion.

      Children using hospice services during the measurement year. Children in hospice may not be able to receive the necessary follow-up care.

      Most Recent Endorsement Activity
      Endorsed Behavioral Health and Substance Use Spring Cycle 2020
      Initial Endorsement
      Last Updated
      Steward Organization
      National Committee for Quality Assurance
      Steward POC email
      measureendorsement@ncqa.org
      Steward Organization Copyright

      © 2020 by the National Committee for Quality Assurance
      1100 13th Street, NW, 3rd floor
      Washington, DC 20005

                Public Comments